Nan Fung
Life Sciences

Focused on innovation and growth in Life Sciences


A global Investor in Life Sciences

Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.

Nan Fung Life Sciences

Global Life Sciences Investment Platform

Pivotal Life Sciences >

Global Life Sciences Asset Management Platform

Pivotal bioVenture Partners (US)

Global Life Sciences VC Investor
(excluding Asia)

Pivotal bioVenture Partners (China)

Life Sciences VC Investor
Based in China

Pivotal CNS >

Global CNS Venture Capital Investor

Pivotal Growth >

Global Life Sciences Growth
Stage Investor

Public Investment >

Life Sciences Public

NFLS Platform Companies >

Building Life Sciences Companies

Fund & Co
Investments >

Investing in Life Sciences Funds


We have an important job to do. Find your role.


The cash won’t stop for Exscientia as it makes a $300M+ Nasdaq debut

Thursday, too, saw Exscientia raise more than just the IPO. In conjunction with the pricing, the Oxford, UK-based biotech got another $160 million in private placements from SoftBank and the Bill and Melinda Gates Foundation. With the debut, details about the big IPO winners are coming into focus. The biggest shareholder is now SoftBank, which will get a 16.3% stake after the offering. CEO Andrew Hopkins is second on the list with 15.8% of shares.

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies
Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing.Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.